NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Acacia Research Corporation (Nasdaq:CBMX) (Nasdaq:ACTG) announced today that its CombiMatrix group’s subsidiary, CombiMatrix Molecular Diagnostics, Inc. (CMDX) has launched a new test that discriminates malignant melanoma from benign moles. The test, based on CombiMatrix Corporation’s CustomArray® platform, is a powerful new molecular diagnostic tool that enables pathologists to resolve difficult-to-diagnose cases through an objective genetic analysis.
